Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PF-06863135”

18 trials

Showing 18 of 18 results

Testing effectiveness (Phase 2)Study completedNCT05228470
What this trial is testing

Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.

Who this might be right for
ElranatamabMyelomaMultiple Myeloma+8 more
Pfizer 39
Large-scale testing (Phase 3)Looking for participantsNCT05623020
What this trial is testing

Learn About Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant or Who Will Not Receive a Transplant as Initial Therapy

Who this might be right for
Multiple Myeloma
Pfizer 1,116
Testing effectiveness (Phase 2)Study completedNCT05014412
What this trial is testing

Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment

Who this might be right for
Multiple Myeloma
Pfizer 86
Early research (Phase 1)Looking for participantsNCT07280013
What this trial is testing

Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

Who this might be right for
Multiple Myeloma (MM)
C4 Therapeutics, Inc. 60
Not applicableNo Longer AvailableNCT05462639
What this trial is testing

Elranatamab Expanded Access Protocol in Adults With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Pfizer
Early research (Phase 1)Looking for participantsNCT05675449
What this trial is testing

A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Pfizer 90
Early research (Phase 1)Study completedNCT04798586
What this trial is testing

MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Pfizer 4
Not applicableNo Longer AvailableNCT05238311
What this trial is testing

Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135)

Who this might be right for
Multiple Myeloma
Pfizer
Testing effectiveness (Phase 2)Active Not RecruitingNCT04649359
What this trial is testing

MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb

Who this might be right for
Multiple Myeloma
Pfizer 187
Not applicableStudy completedNCT05565391
What this trial is testing

Learn About the Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Pfizer 508
Early research (Phase 1)Looking for participantsNCT06215118
What this trial is testing

Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)

Who this might be right for
Multiple Myeloma
Pfizer 87
Not applicableStudy completedNCT05932290
What this trial is testing

Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Pfizer 514
Large-scale testing (Phase 3)Looking for participantsNCT06152575
What this trial is testing

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Who this might be right for
Multiple Myeloma
Pfizer 492
Not applicableStudy completedNCT06504524
What this trial is testing

Compare the Effects of Elranatamab (PF 06863135) Versus Standard of Care (SOC) in Patients With Multiple Myeloma (MM) in Germany and US

Who this might be right for
Multiple Myeloma
Pfizer 633
Large-scale testing (Phase 3)Looking for participantsNCT05020236
What this trial is testing

Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

Who this might be right for
Multiple Myeloma
Pfizer 944
Early research (Phase 1)Study completedNCT03269136
What this trial is testing

PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Pfizer 101
Testing effectiveness (Phase 2)Active Not RecruitingNCT05090566
What this trial is testing

MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma

Who this might be right for
Multiple Myeloma
Pfizer 34
Large-scale testing (Phase 3)Active Not RecruitingNCT05317416
What this trial is testing

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant

Who this might be right for
Multiple Myeloma
Pfizer 811

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation